Kura Oncology (KURA) Receivables - Accured (2020 - 2026)
Kura Oncology (KURA) posted quarterly Receivables - Accured of $4.3 million for Q1 2026, up 10.26% year-over-year from $3.9 million in Q1 2025, and up 13.16% quarter-over-quarter from $3.8 million in Q4 2025.
Kura Oncology (KURA) Receivables - Accured (2020 - 2026) Analysis & Trends
Kura Oncology (KURA) has reported Receivables - Accured for 7 consecutive years, with $4.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables - Accured rose 10.26% year-over-year to $4.3 million; the TTM figure through Mar 2026 stood at $4.3 million (up 10.26% YoY), while the FY2025 annual figure was $3.8 million, up 15.15% from the prior year.
- Receivables - Accured grew to $4.3 million in Q1 2026 per KURA's latest filing, from $3.8 million in the prior quarter.
- Across five years, Receivables - Accured topped out at $4.3 million in Q1 2026 and bottomed at $900000.0 in Q4 2022.
- Historically, Receivables - Accured has averaged $2.1 million across 5 years, with a median of $1.6 million in 2022.
- Annual changes were most pronounced in 2023 — Receivables - Accured tumbled 43.75% — and 2024, when it jumped 200.0%.
- Kura Oncology's Receivables - Accured stood at $900000.0 in 2022, then climbed by 22.22% to $1.1 million in 2023, then surged by 200.0% to $3.3 million in 2024, then gained by 15.15% to $3.8 million in 2025, then advanced by 13.16% to $4.3 million in 2026.
- Business Quant data shows KURA's Receivables - Accured at $4.3 million in Q1 2026, $3.8 million in Q4 2025, and $3.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acc. Int. Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Kura Oncology | 966.11 Mn | 966.11 Mn | 20.63 Mn | 3.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.60 Mn |
| Jun 30, 2026 | 3.60 Mn |
| Mar 31, 2026 | 4.30 Mn |
| Mar 31, 2026 | 4.30 Mn |
| Dec 31, 2025 | 3.80 Mn |
| Dec 31, 2025 | 3.80 Mn |
| Sep 30, 2025 | 3.30 Mn |
| Sep 30, 2025 | 3.30 Mn |
| Jun 30, 2025 | 3.60 Mn |
| Jun 30, 2025 | 3.60 Mn |
| Mar 31, 2025 | 3.90 Mn |
| Mar 31, 2025 | 3.90 Mn |
| Dec 31, 2024 | 3.30 Mn |
| Dec 31, 2024 | 3.30 Mn |
| Sep 30, 2024 | 1.90 Mn |
| Sep 30, 2024 | 1.90 Mn |
| Jun 30, 2024 | 1.90 Mn |
| Jun 30, 2024 | 1.90 Mn |
| Mar 31, 2024 | 1.50 Mn |
| Mar 31, 2024 | 1.50 Mn |